Results of DEFINE and CONFIRM trials of BG 12(Biogen IDEC) in Multiple Sclerosis published in NEJM

Biogen Idec announced that detailed results from its two pivotal clinical trials evaluating oral BG-12 (dimethyl fumarate) for the treatment of Multiple Sclerosis (MS) were published in the Sept. 20, 2012 issue of The New England Journal of Medicine (NEJM). Data from the Phase III DEFINE and CONFIRM studies show that dimethyl fumarate (240 mg), administered twice daily (BID) or three times daily (TID), demonstrated significant and clinically meaningful reductions in MS relapses and brain lesions in patients with relapsing-remitting Multiple Sclerosis (RRMS) compared to placebo, as well as showed benefit in slowing the progression of the disease. Dimethyl fumarate is currently under review by regulatory authorities in the United States, European Union, Australia, Canada and Switzerland.